Aftovaxpur DOE


Foot-and-mouth disease vaccine (inactivated) (multistrain: 1-3 strains out of set of 8)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Aftovaxpur DOE.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 14/11/2018

Authorisation details

Product details
Aftovaxpur DOE
Agency product number
Active substance
Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraq ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; A Turkey 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Arabia  ≥ 6 PD50*; * PD50 – 50% protective dose in cattle as described in Ph. Eur. monograph 0063.
International non-proprietary name (INN) or common name
Foot-and-mouth disease vaccine (inactivated) (multistrain: 1-3 strains out of set of 8)
  • Pigs
  • Cattle
  • Sheep
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Date of issue of marketing authorisation valid throughout the European Union
Contact address
29 avenue Tony Garnier
69007 Lyon

Product information

31/10/2018 Aftovaxpur DOE - EMEA/V/C/002292 - IA/0010/G


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.

Assessment history

How useful was this page?

Add your rating